[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Respironics California, LLC\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":78},{"warningLetters":4,"total":77},[5,32,56],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":27,"recipient_name":28,"body_fetched_at":29,"delivery_method":30,"recipient_title":19,"reference_number":19,"action_taken_date":31,"medical_device_id":19,"response_letter_date":19},1459,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2024-05-14T13:20:00Z\">05\u002F14\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-04-25T04:00:00Z\">04\u002F25\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcalifornia-bread-co-674283-04252024\">California Bread Co.\u003C\u002Fa>"," Division of Human and Animal Food Operations West V","Food Labeling\u002FMisbranded","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Steve S. Shorees, CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Rene A. Garcia, President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>California Bread Co.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>681 Anita St, Ste 106\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Chula Vista\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>91911\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Human and Animal Food Operations West V\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>April 25, 2024\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Shorees and Mr. Garcia:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) inspected your manufacturing facility, located at 681 Anita St, Ste 106, Chula Vista, CA 91911, from October 24 through November 28, 2023. The inspection revealed significant violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP &amp; PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117). Based on FDA’s inspectional findings, we have determined that you did not follow the requirements of the CGMP &amp; PC rule. The failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of the CGMP &amp; PC rule (located in Subparts A, C, D, E, F, and G of Part 117) is prohibited by section 301(uu) of the Act [21 U.S.C. § 331(uu)]. You may find the Act and further information about the CGMP &amp; PC rule through links on FDA's website at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>In addition, your Egg Bread product is also adulterated under section 402(c) of the Act [21 U.S.C. § 342(c)] because it contains a color additive which is unsafe within the meaning of section 721(a) of the Act [21 U.S.C. § 379e(a)]. Further, we found significant violations of the labeling regulations for foods, 21 CFR Part 101. These violations cause your products described below to be misbranded within the meaning of section 403 of the Act [21 U.S.C. § 343].\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, the FDA investigators issued an FDA Form 483 (FDA-483), Inspectional Observations. We received your response describing corrective actions to the FDA-483 on December 13, 2023, with additional documentation received on December 20 and 21, 2023. After reviewing the inspectional findings and your responses, we are issuing this letter to advise you of FDA’s concerns and to provide detailed information describing the findings at your facility. Your responses are addressed below as necessary.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>Hazard Analysis and Risk-Based Preventive Controls (21 CFR 117 Subpart C):\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>1. Your written allergen preventive control did not include procedures, practices, and processes employed for labeling to ensure that all food allergens required to be stated are included on the label for your RTE bread products, as required by 21 CFR 117.135(c)(2)(ii).\u003C\u002Fp>\n\n\u003Cp>Specifically, your hazard analysis for your various bread products (part of your HACCP Plan dated November 2, 2023) identified allergens as a significant hazard requiring a Critical Control Point (CCP) at the packaging\u002Flabeling step. However, your Allergens Management Program did not specifically identify the milk allergen in your sweet whey ingredient. You did not declare the milk allergen on your label for La Torta (Telera) bread products, lot # TAN NOV15, on November 2, 2023. You initiated a voluntary recall the following day covering La Torta (Telera) bread products manufactured back through October 24, 2023.\u003C\u002Fp>\n\n\u003Cp>Your December 13, 2023 response states that you are in the process of ordering new La Torta Bread printed bags, and that you are temporarily placing a corrected printed label on top of old printed bags or clear bags. Your December 21, 2023 response includes a revised process control at the “Labeling and Print bag” step which addresses allergen declaration accuracy. It also addresses application of temporary or sticker labels (i.e., ensuring that correct labels are placed on old\u002Fprinted or clear bags), but it does not appear to address use of printed bags in production (i.e., ensuring that correct preprinted bags are used while packaging finished product). Furthermore, you have not provided supporting documentation demonstrating you have implemented the finished product label check for allergen declarations. In your response to this letter, you should provide your revised written preventive control procedures and completed allergen labeling monitoring records for at least five consecutive days of production.\u003C\u002Fp>\n\n\u003Cp>2. You did not identify and evaluate all known or reasonably foreseeable hazards to determine whether there are hazards requiring a preventive control for your RTE bread products, as required by 21 CFR 117.130(a)(1).\u003C\u002Fp>\n\n\u003Cp>Specifically, your hazard analysis for your various bread products did not identify and evaluate the hazard of undeclared color additives, to determine whether it requires a preventive control. Your facility manufactures bread products (including Egg Bread) containing color additives (including FD&amp;C Yellow #5). FD&amp;C Yellow #5 is known to cause adverse reactions in sensitive individuals, including bronchial asthma in asthmatic individuals. A knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify undeclared FD&amp;C Yellow #5 as a hazard requiring a preventive control. Preventive controls include procedures, practices, and processes necessary to ensure that food manufactured processed, packed, or held by your facility will not be adulterated under section 402 or misbranded under section 403(w) (see 21 CFR 117.135(a)(1) and 21 CFR 117.135(c)(6)), such as during receipt of labels and during packaging\u002Flabeling operations, to ensure FD&amp;C Yellow #5 is declared for products containing this color additive.\u003C\u002Fp>\n\n\u003Cp>You did not have controls in place, as evidenced by your manufacturing and distributing Egg Bread, lot # TAN NOV15, on November 2, 2023, with labels that did not declare the presence of FD&amp;C Yellow #5.\u003Cbr>\n\u003Cbr>\nYour December 13, 2023 response states that Egg Bread bags are currently being labeled with a revised\u002Fcorrected label, placed on top of the printed bags. You are awaiting your bag supplier’s new plates to begin printing corrected new Egg Bread Bags. Your December 21, 2023 response includes a process control for undeclared sub-ingredients in Egg Bread. Your critical limit requires that egg shade containing Yellow #5 and Yellow #6 be specified in the labels or printed bags. However, your critical limit does not include ensuring that Egg Bread labels or bags are used in production while packaging the Egg Bread. Furthermore, you have not provided supporting documentation demonstrating you have implemented the finished product label check for color additive declarations. In your response to this letter, you should provide your revised written procedures for undeclared color additives and completed labeling monitoring records for at least five consecutive days of production.\u003C\u002Fp>\n\n\u003Cp>3. You did not implement your preventive controls procedures to significantly minimize or prevent contamination with the hazard of environmental pathogens in your RTE bread products, as required by 21 CFR 117.135(a)(1).\u003C\u002Fp>\n\n\u003Cp>Specifically, your hazard analysis for your various bread products, including RTE La Torta Bread (Telera Bread), identified the hazard of non-spore forming pathogens such as E. coli, Salmonella, and Listeria as requiring a preventive control at the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” step. Also, your written Sanitation Standard Operating Procedure (SSOP) required that you “[o]bserve equipment for missing parts or parts\u002Fsurfaces that are worn to the extent that debris will accumulate and cause product contamination. When the preventive maintenance technician is involved, he must replace or repair parts\u002Fsurfaces per request or as needed, and document what was done in the work order.” However, during production of your RTE La Torta Bread (Telera Bread), lot # TAN NOV15, on November 2, 2023, FDA investigators observed that the food-contact conveyor belt on the LeMatic slicer (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) was discolored, contained frayed edges, and had an unsmooth metal lace. Your Pre-Operational \u002F Post-Operational Daily Inspection Sheet for November 2, 2o23, found that the packaging areas were “in good order, clean &amp; sanitized.”\u003C\u002Fp>\n\n\u003Cp>Your December 13, 2023 response states that you have \u003Cstrong>(b)(4)\u003C\u002Fstrong> and that your Quality Assurance personnel oversees monitoring for repairs and corrective actions on a \u003Cstrong>(b)(4)\u003C\u002Fstrong> basis. Your corrective actions will be verified during the next FDA inspection.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Color Additive Labeling\u003C\u002Fstrong>\u003Cbr>\nYour Egg Bread products are adulterated within the meaning of section 402(c) of the Act [21 U.S.C. § 342(c)] because the products bear or contain a color additive which is unsafe within the meaning of section 721(a) of the Act [21 U.S.C. § 379e(a)]. Section 721(a) deems a color additive to be unsafe unless its use is in conformity with the color additive listing regulation. Specifically, the listing regulation for FD&amp;C Yellow No. 5 requires that this certified color additive be listed as “FD&amp;C Yellow No. 5” in the ingredient list on the labels of foods for human use that contain FD&amp;C Yellow No. 5 [21 CFR 74.705(d)(2)]. Your Egg Bread product is manufactured with \u003Cstrong>(b)(4)\u003C\u002Fstrong> Egg Shade which contains FD&amp;C Yellow No. 5; however, the label for this product fails to declare FD&amp;C Yellow No. 5 in the ingredient statement.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranding\u003C\u002Fstrong>\u003Cbr>\n1. Your La Torta Bread (72 oz.), Telera (32 oz. and 61 oz.), and Egg Bread (24 oz. and 32 oz.) products are misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in that it is fabricated from two or more ingredients and each ingredient is not declared on the label and the labels fail to declare the ingredients by their common or usual names, as required by 21 CFR 101.4. Specifically:\u003C\u002Fp>\n\n\u003Cp>a. The La Torta Bread product label does not list the ingredients in descending order of predominance by weight, as required by 21 CFR 101.4(a)(1). The label lists yeast after gluten, but your product formula indicates the amount of yeast used to manufacture the product is higher than the amount of gluten.\u003Cbr>\nb. The La Torta Bread and Egg Bread ingredient lists declare the terms “Tempest,” “Viva Fresco Prime 150,” “softener,” “Lovibond red color,” and “Lovibond yellow color,” and the Telera label includes the terms “Tempest” and “softener,” none of which are appropriate common or usual names of ingredients, as required by 21 CFR 101.4(a). The Lovibond is a scale of color measurement and not an ingredient. “Tempest” and “Viva Fresco Prime 150” appear to be brand names. “Softener” appears to be a description of the function of an ingredient; however, it is not a term provided for in 21 CFR 101.4.\u003Cbr>\nc. The term “fresh” on the La Torta Bread, Telera, and Egg Bread ingredient lists is not part of the common or usual name of yeast.\u003Cbr>\nd. The term “Egg Shade Powder” on the Egg Bread product label is not an appropriate declaration for colors.\u003Cbr>\ne. The Telera label declares “Salad Oil (soybean oil)” which is not declared in accordance with 21 CFR 101.4(b)(14).\u003Cbr>\nf. The Egg Bread product label lists “Egg Shade Powder (Yellow#5, Yellow#6);” this is not an appropriate declaration for colors.\u003C\u002Fp>\n\n\u003Cp>2. Your La Torta Bread (72 oz.), Telera (32 oz. and 61 oz.), and Egg Bread (24 oz. and 32 oz.) products are misbranded within the meaning of section 403(q) of the Act [21 U.S.C. 343(q)] in that the nutrition information (e.g., Nutrition Facts label) does not comply with the requirements in 21 CFR 101.9. For example:\u003C\u002Fp>\n\n\u003Cp>a. The nutrients, including the vitamins and minerals, declared in the Nutrition Facts label (NFL) are not in accordance with 21 CFR 101.9(c), and the format is not in accordance with 21 CFR 101.9(d).\u003Cbr>\nb. Your pre-printed bread bags for both La Torta Bread and Egg Bread bear the nutrient content claims, “Cholesterol Free” and “No Trans Fat,” but the NFL does not include declarations for polyunsaturated fat and monounsaturated fat as required by 21 CFR 101.9(c)(2)(iii). Under 21 CFR 101.9(c)(2)(ii) and (iv), mono- and polyunsaturated fats must be declared on the NFL if claims about fatty acids or cholesterol are made on the label or in the labeling of a food other than one that meets the criteria in 21 CFR 101.62(b)(1) for a “fat free” claim.\u003Cbr>\nc. The Egg Bread label does not declare Added Sugars in accordance with 21 CFR 101.9(c)(6) in that the label declares zero grams of added sugar, but light brown sugar is listed as the third most prominent ingredient.\u003Cbr>\nd. The La Torta Bread product label contains a footnote not provided for under 21 CFR 101.9(d)(9).\u003C\u002Fp>\n\n\u003Cp>3. Your Telera (32 oz. and 61 oz.) product is misbranded within the meaning of section 403(i)(1) of the Act [21 U.S.C. 343(i)(1)] in that the product label does not contain an appropriate statement of identity, as required in 21 CFR 101.3(b). “Telera” is a Spanish term and is not an appropriate common or usual name.\u003Cbr>\n\u003Cbr>\n4. Your La Torta Bread (72 oz.) and Telera (32 oz. and 61 oz.) products are misbranded within the meaning of section 403(f) of the Act [21 U.S.C. 343(f)] because the product labels provide information in two languages but do not repeat all required information in both languages. For example, both labels include foreign terms in the statement of identities; however, all required labeling is not also provided in the foreign language, as required by 21 CFR 101.15(c)(2).\u003C\u002Fp>\n\n\u003Cp>5. Your Egg Bread (24 oz. and 32 oz.) product is misbranded within the meaning of section 403(g) of the Act [21 U.S.C. 343(g)]. The product appears to be represented as a food for which a definition and standard of identity have been prescribed by regulations as provided by section 401, but it does not appear to conform to such definition and standard in accordance with 21 CFR 136.110. Specifically, egg bread is subject to the standard of identity in 21 CFR 136.110 which requires, among other things, that the food shall contain not less than 2.56 percent of whole egg solids [21 CFR 136.110(e)(2)]; however, this product fails to contain egg as an ingredient.\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive list of the violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA regulations. This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to legal or regulatory action, including without limitation, seizure or injunction.\u003C\u002Fp>\n\n\u003Cp>In addition to the above violations, we offer the following comments:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The review of your firm’s product labels was limited to the products and sizes listed above. However, you should conduct a review of all your product labels and make appropriate corrections across all products and product sizes.\u003C\u002Fli>\n\t\u003Cli>We note that the Telera, La Torta Bread, and Egg Bread products declare “soybean” in a “Food Allergy Contains” statement. If this statement is meant to be a “Contains” statement as provided for under section 403(w) of the Act, then the words “Food Allergy” need to be removed. Additionally, if the ingredient “soybean oil” is the only soy ingredient, and if it is highly refined soybean oil, then is it is not a major food allergen and it should not be declared in the “Contains” statement. You should review your product formulations to ensure all major food allergens and ingredients are declared appropriately.\u003C\u002Fli>\n\t\u003Cli>As noted above, all the product labels bear the claim “No Trans Fat.” However, FDA has not authorized any nutrient content claims for trans fat, such as “trans fat free,” “no trans fat,” or “zero trans fat.” Under section 403(r)(1)(A) of the Act, a nutrient content claim in food labeling must be made in accordance with a regulation authorizing the use of the claim for the food bearing such a claim not to be misbranded. Although FDA has not defined the term “No Trans Fat” by regulation, we announced in the Federal Register dated July 11, 2003 (68 FR 41507 at 41509) that we would likely consider exercising enforcement discretion for a trans-fat nutrient content claim that is demonstrably true, balanced, adequately substantiated, and not misleading. We point out that, 21 CFR 101.13(i)(3) permits statements about the amount or percentage of a nutrient if the statement does not in any way implicitly characterize the level of the nutrient in the food, and it is not false or misleading in any respect (e.g., \"0 g trans fat”).\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written response should be sent to:\u003C\u002Fp>\n\n\u003Cp>Sergio Chavez, Director, Compliance Branch\u003Cbr>\nFood and Drug Administration\u003Cbr>\nOffice of Human and Animal Foods Division West 5\u003Cbr>\n1201 Harbor Bay Pkwy\u003Cbr>\nAlameda, CA 94502\u003C\u002Fp>\n\n\u003Cp>Refer to Unique Identification Number \u003Cstrong>674283\u003C\u002Fstrong> when replying.\u003C\u002Fp>\n\n\u003Cp>If you would prefer to send your response electronically, please email it to ORAHAFWEST5FirmResponses@fda.hhs.gov. Please include the name of your firm and the Unique Identification Number in the title of the e-mail message.\u003C\u002Fp>\n\n\u003Cp>If you have any questions regarding this letter, please contact Elodie X. Tong-Lin, Compliance Officer, at Elodie.Tong-Lin@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Darla R. Bracy\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations – West Division 5\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Steve S. Shorees, CEO\n\nRecipient Title\n\nMr. Rene A. Garcia, President\n\nCalifornia Bread Co.\n\n681 Anita St, Ste 106\n\nChula Vista, CA 91911\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations West V\n\nUnited States\n\nWARNING LETTER\n\nApril 25, 2024\n\nDear Mr. Shorees and Mr. Garcia:\n\nThe United States Food and Drug Administration (FDA) inspected your manufacturing facility, located at 681 Anita St, Ste 106, Chula Vista, CA 91911, from October 24 through November 28, 2023. The inspection revealed significant violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP & PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117). Based on FDA’s inspectional findings, we have determined that you did not follow the requirements of the CGMP & PC rule. The failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of the CGMP & PC rule (located in Subparts A, C, D, E, F, and G of Part 117) is prohibited by section 301(uu) of the Act [21 U.S.C. § 331(uu)]. You may find the Act and further information about the CGMP & PC rule through links on FDA's website at http:\u002F\u002Fwww.fda.gov.\n\nIn addition, your Egg Bread product is also adulterated under section 402(c) of the Act [21 U.S.C. § 342(c)] because it contains a color additive which is unsafe within the meaning of section 721(a) of the Act [21 U.S.C. § 379e(a)]. Further, we found significant violations of the labeling regulations for foods, 21 CFR Part 101. These violations cause your products described below to be misbranded within the meaning of section 403 of the Act [21 U.S.C. § 343].\n\nAt the conclusion of the inspection, the FDA investigators issued an FDA Form 483 (FDA-483), Inspectional Observations. We received your response describing corrective actions to the FDA-483 on December 13, 2023, with additional documentation received on December 20 and 21, 2023. After reviewing the inspectional findings and your responses, we are issuing this letter to advise you of FDA’s concerns and to provide detailed information describing the findings at your facility. Your responses are addressed below as necessary.\n\nHazard Analysis and Risk-Based Preventive Controls (21 CFR 117 Subpart C):\n\n1. Your written allergen preventive control did not include procedures, practices, and processes employed for labeling to ensure that all food allergens required to be stated are included on the label for your RTE bread products, as required by 21 CFR 117.135(c)(2)(ii).\n\nSpecifically, your hazard analysis for your various bread products (part of your HACCP Plan dated November 2, 2023) identified allergens as a significant hazard requiring a Critical Control Point (CCP) at the packaging\u002Flabeling step. However, your Allergens Management Program did not specifically identify the milk allergen in your sweet whey ingredient. You did not declare the milk allergen on your label for La Torta (Telera) bread products, lot # TAN NOV15, on November 2, 2023. You initiated a voluntary recall the following day covering La Torta (Telera) bread products manufactured back through October 24, 2023.\n\nYour December 13, 2023 response states that you are in the process of ordering new La Torta Bread printed bags, and that you are temporarily placing a corrected printed label on top of old printed bags or clear bags. Your December 21, 2023 response includes a revised process control at the “Labeling and Print bag” step which addresses allergen declaration accuracy. It also addresses application of temporary or sticker labels (i.e., ensuring that correct labels are placed on old\u002Fprinted or clear bags), but it does not appear to address use of printed bags in production (i.e., ensuring that correct preprinted bags are used while packaging finished product). Furthermore, you have not provided supporting documentation demonstrating you have implemented the finished product label check for allergen declarations. In your response to this letter, you should provide your revised written preventive control procedures and completed allergen labeling monitoring records for at least five consecutive days of production.\n\n2. You did not identify and evaluate all known or reasonably foreseeable hazards to determine whether there are hazards requiring a preventive control for your RTE bread products, as required by 21 CFR 117.130(a)(1).\n\nSpecifically, your hazard analysis for your various bread products did not identify and evaluate the hazard of undeclared color additives, to determine whether it requires a preventive control. Your facility manufactures bread products (including Egg Bread) containing color additives (including FD&C Yellow #5). FD&C Yellow #5 is known to cause adverse reactions in sensitive individuals, including bronchial asthma in asthmatic individuals. A knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify undeclared FD&C Yellow #5 as a hazard requiring a preventive control. Preventive controls include procedures, practices, and processes necessary to ensure that food manufactured processed, packed, or held by your facility will not be adulterated under section 402 or misbranded under section 403(w) (see 21 CFR 117.135(a)(1) and 21 CFR 117.135(c)(6)), such as during receipt of labels and during packaging\u002Flabeling operations, to ensure FD&C Yellow #5 is declared for products containing this color additive.\n\nYou did not have controls in place, as evidenced by your manufacturing and distributing Egg Bread, lot # TAN NOV15, on November 2, 2023, with labels that did not declare the presence of FD&C Yellow #5.\n\nYour December 13, 2023 response states that Egg Bread bags are currently being labeled with a revised\u002Fcorrected label, placed on top of the printed bags. You are awaiting your bag supplier’s new plates to begin printing corrected new Egg Bread Bags. Your December 21, 2023 response includes a process control for undeclared sub-ingredients in Egg Bread. Your critical limit requires that egg shade containing Yellow #5 and Yellow #6 be specified in the labels or printed bags. However, your critical limit does not include ensuring that Egg Bread labels or bags are used in production while packaging the Egg Bread. Furthermore, you have not provided supporting documentation demonstrating you have implemented the finished product label check for color additive declarations. In your response to this letter, you should provide your revised written procedures for undeclared color additives and completed labeling monitoring records for at least five consecutive days of production.\n\n3. You did not implement your preventive controls procedures to significantly minimize or prevent contamination with the hazard of environmental pathogens in your RTE bread products, as required by 21 CFR 117.135(a)(1).\n\nSpecifically, your hazard analysis for your various bread products, including RTE La Torta Bread (Telera Bread), identified the hazard of non-spore forming pathogens such as E. coli, Salmonella, and Listeria as requiring a preventive control at the “(b)(4)” step. Also, your written Sanitation Standard Operating Procedure (SSOP) required that you “[o]bserve equipment for missing parts or parts\u002Fsurfaces that are worn to the extent that debris will accumulate and cause product contamination. When the preventive maintenance technician is involved, he must replace or repair parts\u002Fsurfaces per request or as needed, and document what was done in the work order.” However, during production of your RTE La Torta Bread (Telera Bread), lot # TAN NOV15, on November 2, 2023, FDA investigators observed that the food-contact conveyor belt on the LeMatic slicer ((b)(4)) was discolored, contained frayed edges, and had an unsmooth metal lace. Your Pre-Operational \u002F Post-Operational Daily Inspection Sheet for November 2, 2o23, found that the packaging areas were “in good order, clean & sanitized.”\n\nYour December 13, 2023 response states that you have (b)(4) and that your Quality Assurance personnel oversees monitoring for repairs and corrective actions on a (b)(4) basis. Your corrective actions will be verified during the next FDA inspection.\n\nColor Additive Labeling\n\nYour Egg Bread products are adulterated within the meaning of section 402(c) of the Act [21 U.S.C. § 342(c)] because the products bear or contain a color additive which is unsafe within the meaning of section 721(a) of the Act [21 U.S.C. § 379e(a)]. Section 721(a) deems a color additive to be unsafe unless its use is in conformity with the color additive listing regulation. Specifically, the listing regulation for FD&C Yellow No. 5 requires that this certified color additive be listed as “FD&C Yellow No. 5” in the ingredient list on the labels of foods for human use that contain FD&C Yellow No. 5 [21 CFR 74.705(d)(2)]. Your Egg Bread product is manufactured with (b)(4) Egg Shade which contains FD&C Yellow No. 5; however, the label for this product fails to declare FD&C Yellow No. 5 in the ingredient statement.\n\nMisbranding\n\n1. Your La Torta Bread (72 oz.), Telera (32 oz. and 61 oz.), and Egg Bread (24 oz. and 32 oz.) products are misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in that it is fabricated from two or more ingredients and each ingredient is not declared on the label and the labels fail to declare the ingredients by their common or usual names, as required by 21 CFR 101.4. Specifically:\n\na. The La Torta Bread product label does not list the ingredients in descending order of predominance by weight, as required by 21 CFR 101.4(a)(1). The label lists yeast after gluten, but your product formula indicates the amount of yeast used to manufacture the product is higher than the amount of gluten.\n\nb. The La Torta Bread and Egg Bread ingredient lists declare the terms “Tempest,” “Viva Fresco Prime 150,” “softener,” “Lovibond red color,” and “Lovibond yellow color,” and the Telera label includes the terms “Tempest” and “softener,” none of which are appropriate common or usual names of ingredients, as required by 21 CFR 101.4(a). The Lovibond is a scale of color measurement and not an ingredient. “Tempest” and “Viva Fresco Prime 150” appear to be brand names. “Softener” appears to be a description of the function of an ingredient; however, it is not a term provided for in 21 CFR 101.4.\n\nc. The term “fresh” on the La Torta Bread, Telera, and Egg Bread ingredient lists is not part of the common or usual name of yeast.\n\nd. The term “Egg Shade Powder” on the Egg Bread product label is not an appropriate declaration for colors.\n\ne. The Telera label declares “Salad Oil (soybean oil)” which is not declared in accordance with 21 CFR 101.4(b)(14).\n\nf. The Egg Bread product label lists “Egg Shade Powder (Yellow#5, Yellow#6);” this is not an appropriate declaration for colors.\n\n2. Your La Torta Bread (72 oz.), Telera (32 oz. and 61 oz.), and Egg Bread (24 oz. and 32 oz.) products are misbranded within the meaning of section 403(q) of the Act [21 U.S.C. 343(q)] in that the nutrition information (e.g., Nutrition Facts label) does not comply with the requirements in 21 CFR 101.9. For example:\n\na. The nutrients, including the vitamins and minerals, declared in the Nutrition Facts label (NFL) are not in accordance with 21 CFR 101.9(c), and the format is not in accordance with 21 CFR 101.9(d).\n\nb. Your pre-printed bread bags for both La Torta Bread and Egg Bread bear the nutrient content claims, “Cholesterol Free” and “No Trans Fat,” but the NFL does not include declarations for polyunsaturated fat and monounsaturated fat as required by 21 CFR 101.9(c)(2)(iii). Under 21 CFR 101.9(c)(2)(ii) and (iv), mono- and polyunsaturated fats must be declared on the NFL if claims about fatty acids or cholesterol are made on the label or in the labeling of a food other than one that meets the criteria in 21 CFR 101.62(b)(1) for a “fat free” claim.\n\nc. The Egg Bread label does not declare Added Sugars in accordance with 21 CFR 101.9(c)(6) in that the label declares zero grams of added sugar, but light brown sugar is listed as the third most prominent ingredient.\n\nd. The La Torta Bread product label contains a footnote not provided for under 21 CFR 101.9(d)(9).\n\n3. Your Telera (32 oz. and 61 oz.) product is misbranded within the meaning of section 403(i)(1) of the Act [21 U.S.C. 343(i)(1)] in that the product label does not contain an appropriate statement of identity, as required in 21 CFR 101.3(b). “Telera” is a Spanish term and is not an appropriate common or usual name.\n\n4. Your La Torta Bread (72 oz.) and Telera (32 oz. and 61 oz.) products are misbranded within the meaning of section 403(f) of the Act [21 U.S.C. 343(f)] because the product labels provide information in two languages but do not repeat all required information in both languages. For example, both labels include foreign terms in the statement of identities; however, all required labeling is not also provided in the foreign language, as required by 21 CFR 101.15(c)(2).\n\n5. Your Egg Bread (24 oz. and 32 oz.) product is misbranded within the meaning of section 403(g) of the Act [21 U.S.C. 343(g)]. The product appears to be represented as a food for which a definition and standard of identity have been prescribed by regulations as provided by section 401, but it does not appear to conform to such definition and standard in accordance with 21 CFR 136.110. Specifically, egg bread is subject to the standard of identity in 21 CFR 136.110 which requires, among other things, that the food shall contain not less than 2.56 percent of whole egg solids [21 CFR 136.110(e)(2)]; however, this product fails to contain egg as an ingredient.\n\nThis letter is not intended to be an all-inclusive list of the violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA regulations. This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to legal or regulatory action, including without limitation, seizure or injunction.\n\nIn addition to the above violations, we offer the following comments:\n\nThe review of your firm’s product labels was limited to the products and sizes listed above. However, you should conduct a review of all your product labels and make appropriate corrections across all products and product sizes.\n\nWe note that the Telera, La Torta Bread, and Egg Bread products declare “soybean” in a “Food Allergy Contains” statement. If this statement is meant to be a “Contains” statement as provided for under section 403(w) of the Act, then the words “Food Allergy” need to be removed. Additionally, if the ingredient “soybean oil” is the only soy ingredient, and if it is highly refined soybean oil, then is it is not a major food allergen and it should not be declared in the “Contains” statement. You should review your product formulations to ensure all major food allergens and ingredients are declared appropriately.\n\nAs noted above, all the product labels bear the claim “No Trans Fat.” However, FDA has not authorized any nutrient content claims for trans fat, such as “trans fat free,” “no trans fat,” or “zero trans fat.” Under section 403(r)(1)(A) of the Act, a nutrient content claim in food labeling must be made in accordance with a regulation authorizing the use of the claim for the food bearing such a claim not to be misbranded. Although FDA has not defined the term “No Trans Fat” by regulation, we announced in the Federal Register dated July 11, 2003 (68 FR 41507 at 41509) that we would likely consider exercising enforcement discretion for a trans-fat nutrient content claim that is demonstrably true, balanced, adequately substantiated, and not misleading. We point out that, 21 CFR 101.13(i)(3) permits statements about the amount or percentage of a nutrient if the statement does not in any way implicitly characterize the level of the nutrient in the food, and it is not false or misleading in any respect (e.g., \"0 g trans fat”).\n\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nYour written response should be sent to:\n\nSergio Chavez, Director, Compliance Branch\n\nFood and Drug Administration\n\nOffice of Human and Animal Foods Division West 5\n\n1201 Harbor Bay Pkwy\n\nAlameda, CA 94502\n\nRefer to Unique Identification Number 674283 when replying.\n\nIf you would prefer to send your response electronically, please email it to ORAHAFWEST5FirmResponses@fda.hhs.gov. Please include the name of your firm and the Unique Identification Number in the title of the e-mail message.\n\nIf you have any questions regarding this letter, please contact Elodie X. Tong-Lin, Compliance Officer, at Elodie.Tong-Lin@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nDarla R. Bracy\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations – West Division 5","California Bread Co.","california-bread-co-674283-04252024","2026-08-18T06:42:28.856152+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcalifornia-bread-co-674283-04252024","2026-10-26T08:08:10.278472+00:00","Warning Letter","Issued","2024-05-14","674283","Food & Beverages","Division of Human and Animal Food Operations West V","Mr. Steve S. Shorees, CEO","2026-08-20T00:05:08.955+00:00","VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED","2024-04-25",{"id":33,"raw":34,"subject":39,"body_html":41,"body_text":42,"firm_name":43,"letter_id":44,"created_at":45,"fei_number":19,"letter_url":46,"updated_at":47,"action_type":22,"case_status":48,"posted_date":49,"marcs_cms_no":50,"product_type":51,"closeout_date":52,"issuing_office":38,"recipient_name":53,"body_fetched_at":54,"delivery_method":55,"recipient_title":19,"reference_number":19,"action_taken_date":49,"medical_device_id":19,"response_letter_date":19},3509,[35,36,37,38,39,13,40,13],"\u003Ctime datetime=\"2021-02-26T14:00:00Z\">02\u002F26\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-02-26T05:00:00Z\">02\u002F26\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcalifornia-vaping-company-inc-613513-02262021\">California Vaping Company Inc.\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcalifornia-vaping-company-inc-613513-06042021\">\u003Ctime datetime=\"2021-06-08T04:00:00Z\">06\u002F08\u002F2021\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>David Collins and Dakoda Collins\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>California Vaping Company Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4110 Sorrento Valley Blvd Ste C\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>San Diego\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92121\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Sales@CaliVapeCo.com\"> Sales@CaliVapeCo.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:dakoda.collins@calivapeco.com\"> dakoda.collins@calivapeco.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>February 26, 2021&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>WARNING LETTER\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Dear David Collins and Dakoda Collins:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website \u003Cspan>https:\u002F\u002Fcalivapeco.com \u003C\u002Fspan>and determined that the e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. §&nbsp;321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption.&nbsp; Certain tobacco products, including e-liquid, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. §&nbsp;387a(b)) and 21 C.F.R. § 1100.1.&nbsp; Therefore, e-liquids are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act.&nbsp; These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco.&nbsp; \u003Ci>See\u003C\u002Fi> Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Cu>\u003Cspan>\u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fu>\u003C\u002Fspan>. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect.&nbsp; A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)).&nbsp; Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C.&nbsp;§ 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C.&nbsp;§ 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Our review of the website\u003Cspan> https:\u002F\u002Fcalivapeco.com \u003C\u002Fspan>revealed that you manufacture and offer for sale or distribution\u003Cb> \u003C\u002Fb>to customers in the United States e-liquid\u003Cb> \u003C\u002Fb>products\u003Cb> \u003C\u002Fb>without a marketing authorization order including: California Vaping Company Toucan Slam, California Vaping Company Catalina, California Vaping Company Berry Crunch Time, and California Vaping Company Caramel Milk.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>The e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement.&nbsp; Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act.&nbsp; In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act. \u003C\u002Fspan>\u003Cb>&nbsp;\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>Conclusion and Requested Actions\u003Cu> \u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Your firm is a registered manufacturer with over 1,200 products listed with FDA. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations.\u003C\u002Fspan>&nbsp; \u003Cspan>Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction.&nbsp; However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act.&nbsp; Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fhome\">http:\u002F\u002Fwww.fda.gov\u003C\u002Fa>.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Please note your reference number, RW\u003Cspan>2101513\u003C\u002Fspan>, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>If you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301)&nbsp;796-9235 \u003Cspan>or via email at\u003C\u002Fspan> CTPCompliance@fda.hhs.gov.&nbsp;&nbsp;&nbsp; \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Ann Simoneau, J.D.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Director\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Office of Compliance and Enforcement \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Center for Tobacco Products\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>VIA UPS and Electronic Mail\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>cc:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>California Vaping Company\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>9955 Black Mountain Rd\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>San Diego, CA 92126\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>GoDaddy.com, LLC\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>abuse@godaddy.com \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Liquid Web, L.L.C\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>abuse@liquidweb.com\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nDavid Collins and Dakoda Collins\n\nCalifornia Vaping Company Inc.\n\n4110 Sorrento Valley Blvd Ste C\n\nSan Diego, CA 92121\n\nUnited States\n\nSales@CaliVapeCo.com\n\ndakoda.collins@calivapeco.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nFebruary 26, 2021\n\nWARNING LETTER\n\nDear David Collins and Dakoda Collins:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fcalivapeco.com and determined that the e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, e-liquids are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of the website https:\u002F\u002Fcalivapeco.com revealed that you manufacture and offer for sale or distribution to customers in the United States e-liquid products without a marketing authorization order including: California Vaping Company Toucan Slam, California Vaping Company Catalina, California Vaping Company Berry Crunch Time, and California Vaping Company Caramel Milk.\n\nThe e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act.\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 1,200 products listed with FDA. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2101513, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301) 796-9235 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS and Electronic Mail\n\ncc:\n\nCalifornia Vaping Company\n\n9955 Black Mountain Rd\n\nSan Diego, CA 92126\n\nGoDaddy.com, LLC\n\nabuse@godaddy.com\n\nLiquid Web, L.L.C\n\nabuse@liquidweb.com","California Vaping Company Inc.","california-vaping-company-inc-613513-02262021","2026-08-18T06:42:29.460824+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcalifornia-vaping-company-inc-613513-02262021","2026-10-26T08:08:10.365315+00:00","Closed Out","2021-02-26","613513","Tobacco","2021-06-08","David Collins and Dakoda Collins","2026-08-20T03:20:24.806+00:00","VIA UPS and Electronic Mail",{"id":57,"raw":58,"subject":63,"body_html":64,"body_text":65,"firm_name":66,"letter_id":67,"created_at":68,"fei_number":19,"letter_url":69,"updated_at":70,"action_type":22,"case_status":23,"posted_date":71,"marcs_cms_no":72,"product_type":26,"closeout_date":19,"issuing_office":62,"recipient_name":73,"body_fetched_at":74,"delivery_method":75,"recipient_title":19,"reference_number":19,"action_taken_date":76,"medical_device_id":19,"response_letter_date":19},3013,[59,60,61,62,63,13,13,13],"\u003Ctime datetime=\"2021-11-23T14:20:00Z\">11\u002F23\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-11-10T05:00:00Z\">11\u002F10\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcalifornia-terra-garden-inc-616499-11102021\">California Terra Garden Inc.\u003C\u002Fa>","Division of West Coast Imports","Foreign Supplier Verification Program (FSVP)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Xianmin Guan\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>California Terra Garden Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6055 E. Washington Blvd., Suite 200\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Commerce\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>90040\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of West Coast Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>November 10, 2021\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Re: CMS #616499\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Guan:\u003C\u002Fp>\n\n\u003Cp>On May 11, 2021 through June 8, 2021, the Food and Drug Administration conducted a Foreign Supplier Verification Program (FSVP) inspection of California Terra Garden Inc. located at 6055 E. Washington Blvd., Suite 200 Commerce, CA 90040. We also conducted an inspection on January 8, 2020. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\">https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Our current inspection was initiated due to recent recall events associated with mushroom products imported by you from your foreign suppliers. Specifically, retail samples of enoki mushroom products imported from your foreign supplier, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, resulted in positive findings for Listeria monocytogenes by the Michigan Department of Agriculture and Rural Development (MDARD). In response to MDARD’s findings, on April 20, 2021 a voluntary recall of enoki mushrooms was initiated. Additionally, retail samples of enoki mushroom products imported from your foreign supplier, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, resulted in positive findings for \u003Cem>Listeria monocytogenes\u003C\u002Fem> by the Massachusetts Department of Public Health (MDPH). In response to MDPH’s findings, on May 6, 2021 the voluntary recall of enoki mushroom products was expanded. Further, during our FSVP inspection, you were notified by the California Department of Public Health on May 27, 2021, that retail sample of seafood mushroom product, imported from your foreign supplier,&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>, tested positive for \u003Cem>Listeria monocytogenes\u003C\u002Fem>. You conducted a voluntary recall of the imported seafood mushroom products on May 28, 2021.\u003C\u002Fp>\n\n\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1 subpart L for the following foods you import: fresh enoki mushrooms imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>, king oyster mushrooms imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and fresh seafood mushrooms imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Because of these significant violations, your firm is not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the FSVP inspection, our investigator provided you with a Form FDA 483a, FSVP Observations. We acknowledge receipt of your response dated June 22, 2021, and we address your response below.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\n\n\u003Cp>• You must approve your foreign suppliers on the basis of an evaluation of your foreign supplier’s performance and the risk posed by the food, in accordance with 21 CFR 1.505(a), for the products you import. In approving your foreign suppliers and determining the appropriate supplier verification activities, you did not consider the foreign suppliers’ procedures, processes, and practices related to the safety of the food, as required by 1.505(a)(1)(iii)(A). Moreover, your evaluation did not consider applicable FDA food safety regulations and information relevant to the foreign supplier’s compliance with those regulations, as required by 21 CFR 1.505(a)(1)(iii)(B). Specifically, your king oyster mushrooms imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, enoki mushrooms imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and fresh seafood mushrooms imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, are raw agricultural commodities covered under 21 CFR Part 112, Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption (the Produce Safety Rule), but your supplier evaluation and approval did not consider the suppliers’ compliance with the requirements of the Produce Safety Rule.\u003C\u002Fp>\n\n\u003Cp>Your response to the FDA 483a dated June 22, 2021 states that you suspended and canceled orders from your suppliers of enoki and seafood mushrooms and that you intend to “[r]eview the supplier approval process, impose tighter control, and perform more testing.” We are unable to review the adequacy of your response because you did not describe how you would determine that your suppliers are producing the foods in accordance with the Produce Safety Rule. You also did not provide any information regarding your review of processes and procedures related to produce safety for your suppliers of other imported covered produce, such as king oyster mushrooms.\u003C\u002Fp>\n\n\u003Cp>• Your supplier verification activities did not provide adequate assurance that the hazards requiring a control in the foods you import have been significantly minimized or prevented, as required by 21 CFR 1.506(c). FDA has determined that the biological hazards in covered produce require a control, and compliance with the requirements in the Produce Safety Rule significantly minimizes or prevents the biological hazards. However, your verification activities did not include verifying your suppliers’ compliance with the Produce Safety Rule or documenting processes or procedures that provide at least the same level of public health protection as required by the Produce Safety Rule.\u003C\u002Fp>\n\n\u003Cp>Your response to the FDA 483a dated June 22, 2021 states that you are reviewing your supplier approval program and reevaluating vendors in \u003Cstrong>(b)(4)\u003C\u002Fstrong>; however, we cannot evaluate the adequacy of your response because you did not provide any details about this review or your findings. Your response also states that suppliers provided you with certificates, including the Quality Management&nbsp;System Certificate and the HACCP System Certificate, which are commonly issued certificates in \u003Cstrong>(b)(4)\u003C\u002Fstrong>; however, it is unclear if you have evaluated these certifications to assess whether your suppliers are growing and packaging the food in accordance with the Produce Safety Rule. Furthermore, in your response, you state that you are “requesting the GLOBAL GAP which has the same standard as US,” but you did not provide any documentation regarding these standards or comparing them to the level of public health protection provided by the requirements in the Produce Safety Rule. Your response also states that you plan to sample \u003Cstrong>(b)(4)\u003C\u002Fstrong> from your suppliers; however, details of your proposed testing plan were not included in your corrective action response. Finally, although you included a report from \u003Cstrong>(b)(4)\u003C\u002Fstrong> in your response, we are unable to assess how it relates to the FSVP requirements without an English translation.\u003C\u002Fp>\n\n\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of enoki mushrooms imported from your foreign supplier, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, king oyster mushrooms imported from your foreign supplier, \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;and seafood mushrooms imported from your foreign supplier, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. We may place the foods from the identified foreign suppliers on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at \u003Ca href=\"http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)). In addition to the above violations, we also have the following comment:\u003C\u002Fp>\n\n\u003Cp>We note that under 21 CFR 1.506(d)(2), when a hazard in a food will be controlled by the foreign supplier and is one for which there is a reasonable probability that exposure to the hazard will result in serious adverse health consequences or death to humans or animals, you must conduct or obtain documentation of an onsite audit of the foreign supplier before initially importing the food and at least annually thereafter, unless you make an adequate written determination that, instead of such initial and annual onsite auditing, other supplier verification activities and\u002For less frequent onsite auditing are appropriate to provide adequate assurances that the foreign supplier is producing the food in accordance with the relevant food safety standards. Your response to the FDA 483a dated June 22, 2021 states that “[b]ecause of the COVID-19 pandemic, no site audit could be performed. It could only be resumed when there is no travel restriction. So, sampling and testing will play an important role.” Your response further states that you are requesting testing reports from suppliers, as well as sampling and testing \u003Cstrong>(b)(4)\u003C\u002Fstrong> to “make sure the result is acceptable.” We note that FDA has issued guidance for industry concerning alternative verification activities when onsite audits are temporarily impracticable because of COVID-19. The “Temporary Policy Regarding Preventive Controls and FSVP Food Supplier Verification Onsite Audit Requirements During the COVID-19 Public Health Emergency” is available at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F136142\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F136142\u002Fdownload\u003C\u002Fa>. FSVP importers should resume onsite audits within a reasonable period of time after it becomes practicable to do so.\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections, (e.g., documentation of changes you made, such as a copy of your revised FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations. Please provide an English translation of any records that you provide in a language other than English in order to facilitate our review.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to Food and Drug Administration, Attention: Juliane Jung-Lau, Compliance Officer, Division of West Coast Imports, 1201 Harbor Bay Parkway, Alameda, CA 94502. If you have any questions regarding this letter, you may contact Ms. Jung-Lau via email at Juliane.Jung-Lau@fda.hhs.gov. Please reference CMS # 616499 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Dr. Kathleen Turner Program Division Director\u003Cbr>\nDivision of West Coast Imports\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>cc: Ms. Sareth S. Yip, FSVP Manager\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nXianmin Guan\n\nRecipient Title\n\nPresident\n\nCalifornia Terra Garden Inc.\n\n6055 E. Washington Blvd., Suite 200\n\nCommerce, CA 90040\n\nUnited States\n\nIssuing Office:\n\nDivision of West Coast Imports\n\nUnited States\n\nNovember 10, 2021\n\nWARNING LETTER\n\nRe: CMS #616499\n\nDear Mr. Guan:\n\nOn May 11, 2021 through June 8, 2021, the Food and Drug Administration conducted a Foreign Supplier Verification Program (FSVP) inspection of California Terra Garden Inc. located at 6055 E. Washington Blvd., Suite 200 Commerce, CA 90040. We also conducted an inspection on January 8, 2020. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1 subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\n\nOur current inspection was initiated due to recent recall events associated with mushroom products imported by you from your foreign suppliers. Specifically, retail samples of enoki mushroom products imported from your foreign supplier, (b)(4), resulted in positive findings for Listeria monocytogenes by the Michigan Department of Agriculture and Rural Development (MDARD). In response to MDARD’s findings, on April 20, 2021 a voluntary recall of enoki mushrooms was initiated. Additionally, retail samples of enoki mushroom products imported from your foreign supplier, (b)(4), resulted in positive findings for Listeria monocytogenes by the Massachusetts Department of Public Health (MDPH). In response to MDPH’s findings, on May 6, 2021 the voluntary recall of enoki mushroom products was expanded. Further, during our FSVP inspection, you were notified by the California Department of Public Health on May 27, 2021, that retail sample of seafood mushroom product, imported from your foreign supplier, (b)(4), tested positive for Listeria monocytogenes. You conducted a voluntary recall of the imported seafood mushroom products on May 28, 2021.\n\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1 subpart L for the following foods you import: fresh enoki mushrooms imported from (b)(4) located in (b)(4), king oyster mushrooms imported from (b)(4) located in (b)(4), and fresh seafood mushrooms imported from (b)(4) located in (b)(4). Because of these significant violations, your firm is not in compliance with section 805 of the FD&C Act.\n\nAt the conclusion of the FSVP inspection, our investigator provided you with a Form FDA 483a, FSVP Observations. We acknowledge receipt of your response dated June 22, 2021, and we address your response below.\n\nYour significant violations of the FSVP regulation are as follows:\n\n• You must approve your foreign suppliers on the basis of an evaluation of your foreign supplier’s performance and the risk posed by the food, in accordance with 21 CFR 1.505(a), for the products you import. In approving your foreign suppliers and determining the appropriate supplier verification activities, you did not consider the foreign suppliers’ procedures, processes, and practices related to the safety of the food, as required by 1.505(a)(1)(iii)(A). Moreover, your evaluation did not consider applicable FDA food safety regulations and information relevant to the foreign supplier’s compliance with those regulations, as required by 21 CFR 1.505(a)(1)(iii)(B). Specifically, your king oyster mushrooms imported from (b)(4), enoki mushrooms imported from (b)(4), and fresh seafood mushrooms imported from (b)(4), are raw agricultural commodities covered under 21 CFR Part 112, Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption (the Produce Safety Rule), but your supplier evaluation and approval did not consider the suppliers’ compliance with the requirements of the Produce Safety Rule.\n\nYour response to the FDA 483a dated June 22, 2021 states that you suspended and canceled orders from your suppliers of enoki and seafood mushrooms and that you intend to “[r]eview the supplier approval process, impose tighter control, and perform more testing.” We are unable to review the adequacy of your response because you did not describe how you would determine that your suppliers are producing the foods in accordance with the Produce Safety Rule. You also did not provide any information regarding your review of processes and procedures related to produce safety for your suppliers of other imported covered produce, such as king oyster mushrooms.\n\n• Your supplier verification activities did not provide adequate assurance that the hazards requiring a control in the foods you import have been significantly minimized or prevented, as required by 21 CFR 1.506(c). FDA has determined that the biological hazards in covered produce require a control, and compliance with the requirements in the Produce Safety Rule significantly minimizes or prevents the biological hazards. However, your verification activities did not include verifying your suppliers’ compliance with the Produce Safety Rule or documenting processes or procedures that provide at least the same level of public health protection as required by the Produce Safety Rule.\n\nYour response to the FDA 483a dated June 22, 2021 states that you are reviewing your supplier approval program and reevaluating vendors in (b)(4); however, we cannot evaluate the adequacy of your response because you did not provide any details about this review or your findings. Your response also states that suppliers provided you with certificates, including the Quality Management System Certificate and the HACCP System Certificate, which are commonly issued certificates in (b)(4); however, it is unclear if you have evaluated these certifications to assess whether your suppliers are growing and packaging the food in accordance with the Produce Safety Rule. Furthermore, in your response, you state that you are “requesting the GLOBAL GAP which has the same standard as US,” but you did not provide any documentation regarding these standards or comparing them to the level of public health protection provided by the requirements in the Produce Safety Rule. Your response also states that you plan to sample (b)(4) from your suppliers; however, details of your proposed testing plan were not included in your corrective action response. Finally, although you included a report from (b)(4) in your response, we are unable to assess how it relates to the FSVP requirements without an English translation.\n\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1 subpart L.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of enoki mushrooms imported from your foreign supplier, (b)(4), king oyster mushrooms imported from your foreign supplier, (b)(4) and seafood mushrooms imported from your foreign supplier, (b)(4). We may place the foods from the identified foreign suppliers on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)). In addition to the above violations, we also have the following comment:\n\nWe note that under 21 CFR 1.506(d)(2), when a hazard in a food will be controlled by the foreign supplier and is one for which there is a reasonable probability that exposure to the hazard will result in serious adverse health consequences or death to humans or animals, you must conduct or obtain documentation of an onsite audit of the foreign supplier before initially importing the food and at least annually thereafter, unless you make an adequate written determination that, instead of such initial and annual onsite auditing, other supplier verification activities and\u002For less frequent onsite auditing are appropriate to provide adequate assurances that the foreign supplier is producing the food in accordance with the relevant food safety standards. Your response to the FDA 483a dated June 22, 2021 states that “[b]ecause of the COVID-19 pandemic, no site audit could be performed. It could only be resumed when there is no travel restriction. So, sampling and testing will play an important role.” Your response further states that you are requesting testing reports from suppliers, as well as sampling and testing (b)(4) to “make sure the result is acceptable.” We note that FDA has issued guidance for industry concerning alternative verification activities when onsite audits are temporarily impracticable because of COVID-19. The “Temporary Policy Regarding Preventive Controls and FSVP Food Supplier Verification Onsite Audit Requirements During the COVID-19 Public Health Emergency” is available at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F136142\u002Fdownload. FSVP importers should resume onsite audits within a reasonable period of time after it becomes practicable to do so.\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections, (e.g., documentation of changes you made, such as a copy of your revised FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations. Please provide an English translation of any records that you provide in a language other than English in order to facilitate our review.\n\nPlease send your reply to Food and Drug Administration, Attention: Juliane Jung-Lau, Compliance Officer, Division of West Coast Imports, 1201 Harbor Bay Parkway, Alameda, CA 94502. If you have any questions regarding this letter, you may contact Ms. Jung-Lau via email at Juliane.Jung-Lau@fda.hhs.gov. Please reference CMS # 616499 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nDr. Kathleen Turner Program Division Director\n\nDivision of West Coast Imports\n\ncc: Ms. Sareth S. Yip, FSVP Manager","California Terra Garden Inc.","california-terra-garden-inc-616499-11102021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcalifornia-terra-garden-inc-616499-11102021","2026-10-26T08:08:10.332531+00:00","2021-11-23","616499","Xianmin Guan","2026-08-20T02:25:33.162+00:00","Via Express Delivery","2021-11-10",3,{"510k":79,"classification":80,"enforcement":81,"event":82,"event_backfill":83,"pma":84,"warning_letter":85},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]